butabarbital will minimize the level or result of doravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
butabarbital will lessen the level or effect of carvedilol by influencing hepatic enzyme CYP2C9/10 metabolism. Use Warning/Watch.
butabarbital will reduce the extent or impact of alprazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
It is essential that your doctor check your development at normal visits to be certain this medication is Operating appropriately. Blood and urine exams may very well be required to check for unwanted results.
butabarbital will minimize the level or effect of duvelisib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration with a powerful CYP3A inducer decreases duvelisib place under the curve (AUC), which may reduce duvelisib efficacy.
butabarbital will reduce the extent or effect of etravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
butabarbital will minimize the extent or outcome of cinacalcet by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
butabarbital will reduce the extent or outcome of almotriptan by affecting hepatic/intestinal enzyme CYP3A4 website metabolism. Use Caution/Watch.
People with acute or Long-term ache (besides pain right after surgical treatment or chemotherapy)—Use with caution. May well trigger an opposite impact to 1 that is Ordinarily envisioned and mask signs and symptoms of other unidentified diseases.
butabarbital will lessen the extent or outcome of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is actually a sensitive CYP3A4 substrate. Coadministration with sturdy or reasonable CYP3A4 inducers is contraindicated.
butabarbital decreases levels of atrasentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Coadministration with robust or reasonable CYP3A inducers is predicted to lower atrasentan systemic publicity, which can lessen efficacy. .
Critique your fiscal support package by logging in to the myHeliotrope account together with your new Purchase e-mail.
butabarbital will lessen the level or effect of repaglinide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
butabarbital boosts consequences of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. CYP3A4 inducers could boost the metabolism of ifosfamide to its Lively alkylating metabolites.